Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices 9521 

Dated: February 9, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03015 Filed 2–12–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Pediatric Formulations of 

Select Second Line Drugs for Treating 

Tuberculosis (Topic 97). 

Date: February 22, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mario Cerritelli, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892, 240–669–5199, 

cerritem@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Pediatric Formulations of 

Select Second Line Drugs for Treating 

Tuberculosis (Topic 96). 

Date: February 24, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mario Cerritelli, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892, 240–669–5199, 

cerritem@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase II: Pediatric Formulations of 

Select Second Line Drugs for Treating 

Tuberculosis (Topic 97). 

Date: February 24, 2021. 

Time: 4:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mario Cerritelli, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F58, 

Rockville, MD 20892, 240–669–5199, 

cerritem@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 9, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03016 Filed 2–12–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak at 240–627–3705 or 

Chris.Kornak@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Replication-Competent Adenovirus 

Type 4 SARS–CoV–2 Vaccines and 

Their Use 

Description of Technology 

NIAID has produced recombinant 

adenovirus type 4 (Ad4), SARS–CoV–2 

spike, vectors for administration to 

humans. These recombinant vaccines 

permit rapid development of high levels 

of neutralizing antibodies to SARS– 

CoV–2 in experimental animals. This 

vaccine is designed to improve the 

durability of the immune response by 

inducing mucosal and systemic 

immunity. Further, this system should 

be incredibly simple and efficient when 

producing vaccine at scale. This 

technology is available for licensing for 

commercial development in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

as well as for further development and 

evaluation under a research 

collaboration. 

Potential Commercial Applications 

• Vaccine composition(s) 

Competitive Advantages 

• Stimulates a durable immune 

response; 

• Induction of mucosal and systemic 

immunity; 

• Potential for transmission 

interruption; 

• Intranasal administration minimizes 

the impact of pre-existing immunity; 

• Notable improvement for 

manufacturing yield and cost, ease of 

administration, and distribution as 

compared to current candidates. 

Inventor: Mark Connors, M.D. (NIAID) 

Publications: Matsuda et al. Journal of 

Clinical Investigation, 2021. (https://

doi.org/10.1172/JCI140794). Matsuda et 

al., Science Immunology 2019 (https:// 

doi.org/10.1126/sciimmunol.aau2710). 

Intellectual Property: HHS Reference 

E–055–2021; Application No. 63/ 

138,221. 

Licensing Contact: To license this 

technology, please contact Chris Kornak 

at chris.kornak@nih.gov. 


khammond on DSKJM1Z7X2PROD with NOTICES